|
|
Blood, 1 April 2006, Vol. 107, No. 7, pp. 2702-2704.
Prepublished online as a Blood First Edition Paper on December 6, 2005; DOI 10.1182/blood-2005-07-2854.
 Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS
Brief report
Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations
Gail Dallalio,
Erin Law, and
Robert T. Means, Jr
From the Medical and Research Services, Lexington Department of Veterans Affairs Medical Center and the Hematology/Oncology Division/Markey Cancer Center, University of Kentucky College of Medicine, Lexington.
The anemia of chronic disease (ACD) results from 3 major processes: slightly shortened red cell survival, impaired reticuloendothelial system iron mobilization, and impaired erythropoiesis. Hepcidin is an acute-phase protein with specific iron regulatory properties, which, along with the anemia seen with increased hepcidin expression, have led many to consider it the major mediator of ACD. However, if hepcidin is the major factor responsible for ACD, then it should also contribute to the impaired erythropoiesis observed in this syndrome. Erythroid colony formation in vitro was inhibited by hepcidin at erythropoietin (Epo) concentrations less than or equal to 0.5 U/mL but not at Epo 1.0 U/mL. At Epo concentrations of 0.3 U/mL, HCD57 erythroleukemia cells exposed to hepcidin exhibit decreased expression of the antiapoptotic protein pBad compared with controls. These studies suggest that hepcidin may contribute to anemia in ACD not only through effects on iron metabolism, but also through inhibition of erythroid progenitor proliferation and survival.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. Veuthey, M. C. D'Anna, and M. E. Roque
Role of the kidney in iron homeostasis: renal expression of Prohepcidin, Ferroportin, and DMT1 in anemic mice
Am J Physiol Renal Physiol,
October 1, 2008;
295(4):
F1213 - F1221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Swinkels and J. F. M. Wetzels
Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?
Nephrol. Dial. Transplant.,
August 1, 2008;
23(8):
2450 - 2453.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sharma, E. Nemeth, Y.-H. Chen, J. Goodnough, A. Huston, G.D. Roodman, T. Ganz, and A. Lichtenstein
Involvement of Hepcidin in the Anemia of Multiple Myeloma
Clin. Cancer Res.,
June 1, 2008;
14(11):
3262 - 3267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Adamson
The Anemia of Inflammation/Malignancy: Mechanisms and Management
Hematology,
January 1, 2008;
2008(1):
159 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Roy, H. H. Mak, I. Akpan, G. Losyev, D. Zurakowski, and N. C. Andrews
Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation
Blood,
May 1, 2007;
109(9):
4038 - 4044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Yoon, Y. D. Pastore, V. Divoky, E. Liu, A. E. Mlodnicka, K. Rainey, P. Ponka, G. L. Semenza, A. Schumacher, and J. T. Prchal
Hypoxia-inducible Factor-1 Deficiency Results in Dysregulated Erythropoiesis Signaling and Iron Homeostasis in Mouse Development
J. Biol. Chem.,
September 1, 2006;
281(35):
25703 - 25711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Truksa, H. Peng, P. Lee, and E. Beutler
Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6
PNAS,
July 5, 2006;
103(27):
10289 - 10293.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
